Saving Capital Gains Tax on SpaceX Stock: Exchange Fund, Donor-Advised Fund, or Charitable Remainder Unitrust — and What the Price Decline Changes

Short answer. A SpaceX shareholder saving capital gains tax after the IPO has three principal instruments, and they solve different problems. An exchange fund diversifies a concentrated position without a current sale, at the price of a multi-year holding period and no cash. A donor-advised fund eliminates the gain on donated shares and produces a fair-market-value deduction, at the price of giving the shares away entirely. A charitable remainder unitrust sells the shares free of trust-level tax, converts the full pre-tax proceeds into a diversified payout stream, and spreads gain recognition across the payout years. The stock's fall below its $135 IPO price splits the shareholder base: pre-IPO holders at low basis still carry large embedded gains and remain candidates for all three; holders who received shares at or near the IPO price may now hold losses, for whom none of these instruments is the right tool.

Jurisdiction: Federal, with a California overlay for income tax conformity

Primary Statutes: IRC §664, §664(b), §664(c)(1), §664(d)(2), §170(b)(1)(C), §68, §4941, §4947(a)(2), §7520; Treas. Reg. §1.664-3(b); Cal. Rev. & Tax. Code §17755

Key Authorities: Rev. Rul. 78-197, 1978-1 C.B. 83; Ferguson v. Commissioner, 174 F.3d 997 (9th Cir. 1999); Gottlieb, Journal of Financial Planning (August 2026) Monte Carlo study; SpaceX final prospectus (Form 424B4, filed June 12, 2026)

Last Reviewed: August 2026

Category: Charitable Remainder Trusts — Concentrated Stock

By Klaus Gottlieb, Esq.

What the price decline changed — and for whom

SpaceX priced its June 2026 IPO at $135. The stock ran to a market value above $2.6 trillion, then gave most of the run back: it closed below the IPO price for the first time on July 15 and has traded through early August roughly a third below its post-IPO high. That move rewrote the tax planning question, because it split shareholders into two groups with opposite problems.

• Pre-IPO holders at low basis. An employee or early investor whose basis is a few dollars a share still holds a position that is overwhelmingly embedded gain at today's price. The capital gains problem is smaller than it was at the top, but it did not go away — and every lockup release still converts paper appreciation into a taxable decision. This group is the audience for the three instruments this article compares.

• Holders who acquired at or near the IPO price. An RSU holder whose shares vested near $135 has basis near $135 and, at current prices, a loss. Nothing in this article is built for a loss position. Selling recognizes a capital loss usable against other gains; contributing loss stock to a charitable vehicle wastes the loss, because the charity's sale does not deliver it to anyone. The first planning step for this group is a lot-by-lot basis review, not a trust.

Basis by lot, not the headline price, therefore decides which instrument — if any — fits. The rest of this article assumes the low-basis holder.

The lockup schedule, verified against the offering documents

The lockup is staged, and the staging structures every strategy below. Per the final prospectus and the underwriting agreement filed with the SEC:

• 20% of locked shares released following the Q2 2026 earnings report (reported August 4; shares salable from August 6).

• An additional early tranche of up to 10% was conditioned on the stock closing at least 30% above the $135 IPO price on five of the ten trading sessions ending August 4. Given the price path, that condition failed — this tranche did not release.

• 7% at each of days 70, 90, 105, 120, and 135 after the offering.

• 28% following the Q3 2026 earnings report.

• The remainder at day 180 — December 8, 2026 — when the underwriting agreement's base restricted period ends.

• Elon Musk and certain major holders are under a separate 366-day restriction with no early-release provisions.
  

Two consequences. First, a shareholder does not face one selling decision; there are as many as six windows between August and December, each a separate opportunity to sell, donate, or contribute. Second, any transfer into a trust or fund before a release date must be permitted by the shareholder's individual lockup agreement — transfer provisions vary, and the agreement controls.

The three instruments, compared

The baseline is an outright sale: a California resident in the top brackets surrenders roughly 37% of the gain — 20% federal capital gains, 3.8% net investment income tax, and 13.3% California, which taxes capital gain as ordinary income. Each instrument below avoids or restructures that result differently.

	Exchange fund	Donor-advised fund	Charitable remainder unitrust
What happens to the shares	Contributed to a pooled partnership; shareholder receives a diversified interest in the pool	Donated outright; sponsoring organization sells and holds proceeds for grantmaking	Contributed to an irrevocable trust; trust sells and reinvests full pre-tax proceeds
Gain on the SpaceX shares	Not recognized at contribution; basis carries into the fund interest	Never recognized by the donor	Not recognized by the trust at sale (§664(c)(1)); carried out to the beneficiary over the payout years under §664(b)
Deduction	None	Fair market value, subject to the 30%-of-AGI limit for appreciated long-term stock with five-year carryforward (§170(b)(1)(C))	Present value of the charitable remainder, same 30%/carryforward regime; computed at the contribution month's §7520 rate (5.2% for August 2026)
Cash to the shareholder	None until exit; typical funds require a seven-year holding period before redemption in kind	None, ever — the gift is complete	Annual unitrust payout, a fixed percentage of trust value revalued each year, for life or a term up to 20 years
What is given up	Liquidity and control for years; fund fees; the deferred gain survives in the substituted basis	The property itself	Access to principal; the remainder passes irrevocably to charity; Form 5227 administration and the self-dealing rules (§4947(a)(2), §4941)
Fits best when	The goal is diversification only, no cash need, no charitable intent	The dollars were headed to charity anyway; deduction wanted this year	Low basis, long horizon, income need, and comfort with a charitable remainder

When the exchange fund is the better answer

A shareholder seeking only to diversify a concentrated position—without an income need or charitable objective—is generally not a CRUT candidate. An exchange fund addresses that problem more directly by allowing appreciated shares to be contributed to a pooled partnership portfolio. The contribution is generally tax-free under I.R.C. § 721(a), provided the partnership is not treated as an investment company under §§ 721(b) and 351(e). Because contributions of different securities ordinarily create diversification, Treas. Reg. § 1.351-1(c) requires the fund to be structured so that investment assets do not exceed the applicable 80-percent threshold.

The tradeoffs are illiquidity, fees, and high minimum investments. Although seven years is a customary holding period rather than an express statutory requirement, it corresponds to the anti-mixing-bowl rules of §§ 704(c)(1)(B) and 737. The tax is deferred, not eliminated: the shareholder receives a carryover basis under § 722, and the partnership takes a carryover basis under § 723. For an investor who wants to reduce single-stock risk without presently liquidating the wealth, and who can tolerate the holding period, an exchange fund may be the cleanest instrument available.

When the donor-advised fund is the better answer

For dollars that were going to charity regardless, the DAF dominates. The donation of appreciated long-term shares produces a fair-market-value deduction against up to 30% of adjusted gross income with a five-year carryforward (§170(b)(1)(C)), the embedded gain is never taxed to anyone, and administration is nearly nil. In a year when lockup-window sales push income up, donating one tranche while selling another pairs the deduction against the recognition. What the DAF cannot do is return anything: no income stream, no retained interest. It is a completed gift, and it should be sized like one. The 0.5%-of-AGI floor on charitable deductions and the §68 overall limitation, both effective in 2026, trim the net benefit at the margin and belong in any projection.

What the CRUT does that neither of the others can

The charitable remainder unitrust is the only instrument of the three that produces all of: a tax-free sale, a retained income stream, and a current deduction. The shareholder transfers shares to an irrevocable trust under §664; the trust sells without recognizing gain (§664(c)(1)) and reinvests the full pre-tax proceeds; the shareholder receives a fixed-percentage payout of the trust's annually revalued balance for life or a term of up to 20 years; the remainder passes to charity or a donor-advised fund.

The gain is deferred, not erased, and the mechanism is §664(b): each payout carries out the trust's income in a fixed order — ordinary income first, then capital gain, then other income, then corpus. The gain from the SpaceX sale is therefore recognized by the beneficiary across many payout years instead of in one sale year. That ordering is the subject of its own forthcoming analysis on this site; for present purposes the point is that the deferral spreads and smooths the tax, and the reinvested pre-tax proceeds compound in the meantime.

My Monte Carlo study in the Journal of Financial Planning (August 2026) quantifies when this structure outperforms an outright sale and reinvestment: the advantage is driven by low basis — the benefit rises steeply as basis falls, a cliff rather than a slope — and by horizon length; longevity beyond actuarial expectation compounds it; and the §7520 rate matters far less than basis, fees, and design. In the scenarios where the CRUT wins, the shareholder's own terminal wealth typically exceeds the outright-sale path, so the charitable remainder is financed by tax savings rather than by forgone personal wealth. Where those conditions fail, the remainder is a real personal cost, and charitable intent has to carry it.

The 10% remainder test, by age

Every CRUT must pass §664(d)(2): the present value of the charitable remainder must be at least 10% of the value contributed. The test binds hardest for young shareholders on life-contingent designs. At the August 2026 §7520 rate of 5.2%: at age 25 no life-contingent design qualifies and a term of years is required; at 28 a single-life design qualifies only at the 5% minimum payout; at 30 both single-life and longer-of designs qualify near 5%; at 36 roughly 6% is supportable; at 45, roughly 7.8% single-life or 6.9% on a longer-of design. No shareholder is too young for a term CRUT of up to 20 years, which has no measuring life. Age and payout rate dominate the computation; the §7520 rate barely moves it.

Staged lockup releases and the additions clause

A CRUT drafted to accept additional contributions (Treas. Reg. §1.664-3(b)) matches the staggered lockup naturally: draft once, contribute shares as tranches release. Each addition is valued at its own contribution date and generates its own deduction at that month's §7520 rate. Funding can run per-release, in two stages, or in a single year-end contribution — trading diversification speed against administrative events.

Two constraints bind every funding pattern. Shares must be contributed before any binding sale arrangement exists: Rev. Rul. 78-197, 1978-1 C.B. 83, sets the formal line, and Ferguson v. Commissioner, 174 F.3d 997 (9th Cir. 1999), taxed donors where the sale had ripened to practical certainty even without a binding obligation. And the shareholder's individual lockup agreement must permit the transfer — a point to confirm in the document, not assume.

The loss-lot overlay the price decline created

The same portfolio can now hold both problems. A long-tenured employee may hold pre-IPO lots at near-zero basis alongside RSU lots vested near $135 that stand at a loss. The instruments then divide by lot: low-basis lots are the raw material for the CRUT, DAF, or exchange fund; loss lots belong outside all three, where selling them recognizes losses that can absorb gains from lockup-window sales of other lots. Contributing a loss lot to any charitable vehicle forfeits the loss. Lot-level basis records from the equity administration system are the first document to pull, before any design conversation.

The California overlay

California conforms to the federal charitable remainder trust rules (Cal. Rev. & Tax. Code §17755): the trust-level exemption and the character-based taxation of payouts replicate at the state level. Because California taxes capital gain as ordinary income at rates up to 13.3%, the deferral is worth more to a California resident than the federal arithmetic alone suggests. A shareholder contemplating a move out of state during the payout term needs a separate residency analysis before relying on that assumption.

The calendar between now and December 8

The Q3-earnings tranche of roughly 28% and the final December 8 release remain ahead. A trust must be drafted, executed, and funded — custodial account open, charitable beneficiary named — before shares can move, and a 2026 deduction requires completing that sequence in 2026. The window for deliberate design is now; it will not be in the last weeks of December.

What a shareholder should assemble

• Personal lockup tranche assignments and release dates, and the individual lockup agreement's transfer provisions

• Basis by lot, separating pre-IPO lots from IPO-era vestings

• Realistic annual cash-flow needs, which decide between the DAF (none), exchange fund (none for years), and CRUT (annual payout)

• Charitable intent, honestly assessed — it is load-bearing for two of the three instruments

• Existing sale commitments, 10b5-1 plans, or standing instructions, which interact with Rev. Rul. 78-197 and Ferguson
  

For a quick estimate of the CRUT deduction at the live §7520 rate, use the CalCRUT deduction calculator. For a full comparison of the CRUT against hold-and-draw, hold-to-death step-up, and liquidate-and-reinvest benchmarks under your own basis and horizon, run the numbers at QuantiCRUT. To discuss your situation with me, schedule a call.

This article is provided for general information. It is not legal advice and not tax advice, and reading it does not create an attorney-client relationship. Consult a qualified attorney about your own situation.